SCHEMBL3119794

SCHEMBL3119794

O=C1CCN(OCc2ccccc2)CC1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.46
POLB P06746 1/20 0.44
TSHR P16473 2/20 0.42
KMT2A Q03164 2/20 0.41
PKM P14618 1/20 0.41
HTT P42858 1/20 0.40
ALOX15 P16050 1/20 0.40
L3MBTL1 Q9Y468 2/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
GAA P10253 1/20 0.39
DDB1 Q16531 1/20 0.38
CRBN Q96SW2 1/20 0.38
KCNA5 P22460 1/20 0.38
IDO1 P14902 1/20 0.38
CYP2C19 P33261 1/20 0.37
MEN1 O00255 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10382845 0.93 ALDH1A1 (0.41) ALDH1A1POLBTSHRKMT2APKM
SCHEMBL2982806 0.80 TSHR (0.46) ALDH1A1TSHRNPC1RAB9AIDO1
SCHEMBL15094370 0.80 TSHR (0.46) ALDH1A1TSHRIDO1
SCHEMBL9744353 0.79 SIGMAR1 (0.47) TSHRNPC1RAB9A
Hydrochloric Acid SCHEMBL2978407 0.79 LMNA (0.46) ALDH1A1TSHRNPC1RAB9AIDO1
SCHEMBL447549 0.79 SIGMAR1 (0.47) TSHRNPC1RAB9A
SCHEMBL2917851 0.77 L3MBTL1 (0.46) ALDH1A1POLBKMT2APKML3MBTL1
Bromide SCHEMBL28805308 0.77 SIGMAR1 (0.46) TSHRNPC1RAB9A
SCHEMBL27166512 0.76 LMNA (0.47) ALDH1A1TSHRKMT2ACYP2C19MEN1
SCHEMBL28598923 0.76 TSHR (0.50) ALDH1A1TSHRIDO1CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8916552-B2 Pharmaceutical combinations ASTEX THERAPEUTICS LIMITED (GB) 2014-12-23 US disclosed
US-8362255-B2 Process for the manufacture of [phenylsulfanylphenyl]piperidines H. LUNDBECK A/S (DK) 2013-01-29 US disclosed
EP-2260024-B1 PROCESS FOR THE MANUFACTURE OF [PHENYLSULFANYLPHENYL] PIPERIDINES LUNDBECK & CO AS H (DK) 2011-12-28 EP disclosed
US-20110054178-A1 PROCESS FOR THE MANUFACTURE OF [PHENYLSULFANYLPHENYL]PIPERIDINES H. LUNDBECK A/S (DK) 2011-03-03 US disclosed
US-20100179145-A1 PHARMACEUTICAL COMBINATIONS ASTEX THERAPEUTICS LIMITED (GB) 2010-07-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110054178-A1 PROCESS FOR THE MANUFACTURE OF [PHENYLSULFANYLPHENYL]PIPERIDINES NPEPPS, UMPS, DHPS ALDH1A1 575/4885POLB 939/4885TSHR 3708/4885
US-20100179145-A1 PHARMACEUTICAL COMBINATIONS GSK3B, CDK1, CDK6 ALDH1A1 3443/4885POLB 2362/4885TSHR 470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.